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Melancholic mind: The artist Edvard Munch (1863–1944) suffered from severe anxiety and has 
in his work depicted various states of emotional distress, including depression: this painting is 
called Evening. Melancholy I. (1896). (Image: Wikipedia.)speed in complex tasks. For example, 
one important constraint to reduce 
complexity is attention, the selection of 
a subset of the input data or a subset 
of potential outputs that focus on the 
most relevant options. Strategies are 
now being developed to operationalize 
‘attention’ and other biologically based 
approaches, and transport them to 
intelligent devices. 
And in a third essay, Buckholtz and 
Faigman bring in the law. After all, 
once the new brain–machine interfaces 
are in place, who is to blame when 
your prosthetic arm kills someone? 
These instances where we might look 
to the technology to find responsibility 
for our actions shade into cases 
where our better understanding of the 
neuroscience of behavior suggests 
neural sources for antisocial acts. 
We can blame murder on Ambien 
or Twinkies, on YYX chromosomes 
or on just being male. Where does 
responsibility fall, morally and legally, 
once we have more comprehensive 
explanations of violent behavior from 
neuroscience. How reliable is the use 
of neuroscience as evidence in court. 
Buckholtz and Faigman consider 
the difficulty of evaluating scientists’ 
testimony as well as the use of fMRI or 
other biomarkers of lying, and the use 
of predictive constraints on individuals 
with neural correlates of antisocial 
behavior. Neuroscience, perhaps more 
than any other science, will become 
increasingly involved in deciding 
legal cases and policy. Buckholtz 
and Faigman offer some guidance to 
the issues that will be raised as this 
progresses. 
In reading through these reviews, 
primers, and essays, it is clear that 
neuroscience is now a major player 
in medicine and the development of 
new learning and legal methods. At 
one time, a ‘moon shot’ meant that 
your project was ambitious but had 
almost no chance of succeeding. But, 
of course, we did land on the moon, 
and neuroscience has now reached a 
level of maturity and progress where a 
‘moon shot’ for neuroscience should 
mean just that, a massive moon-
landing level of investment to bring the 
fruits of neuroscience, many on display 
in this special issue, to society.
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Depression has become one of the biggest health problems globally, but in 
certain places more than in others, suggesting cultural as well as biological 
causes. Neuroscientists are only beginning to understand underlying processes 
and to develop effective treatments for those cases where conventional 
psychotherapy and drugs fail. Michael Gross reports.
Silver linings for patients with depression?The recent death by suicide of 
Hollywood actor Robin Williams 
triggered a global discussion about 
mental health, bringing out all the 
manifold questions, uncertainties, 
misconceptions and prejudices 
that surround problems like major 
depressive disorder (depression) 
and bipolar disorder, which is what 
Williams reportedly suffered from and 
which involves alternating phases of 
depression and euphoria. 
By its very nature, views on a 
suicide in the state of depression 
depend on people’s philosophy and 
outlook on life. Reactions range from 
the view that depression is a deadly 
disease like cancer and suicide is 
just its fatal symptom, through to the description of suicide as an 
act of free will designed to escape 
an unbearable situation. Charities 
like the Samaritans and Mind 
have warned that the latter view, if 
propagated in the media, may trigger 
further suicides, as may the reporting 
of excessive detail of the ways and 
means employed in the act. However, 
with the global media competing 
over this exceptional story, this 
advice was frequently neglected in 
the reporting. 
In the wake of Williams’ death, 
attention turned to the broader issues 
of depression, which is widespread 
but still widely misunderstood. Major 
depression, according to a definition 
from US psychiatrist Allen Frances, 
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Mood control: Neurobiological studies of 
mood disorders have linked the formation of 
neurons in the hippocampus to mood disor-
ders such as depression. (Image: Life Science 
Databases (LSDB)/Wikimedia Commons.)“must be dense (i.e., present for most 
of the day, almost every day); must 
last at least a few weeks; and must 
be severe enough to cause clinically 
significant impairment” (quoted from 
Essentials of Psychiatric Diagnosis). 
That sounds terrifying enough to 
justify an urgent call to a medical 
practitioner, but sufferers who would 
need medical help are still facing 
unhelpful comments like “just get over 
it” from people who fail to understand 
that mental illness is just as real as 
physical disorders. 
Such misconceptions may be part 
of the reason why only a minority 
of sufferers are actually getting the 
medical help they require. The new 
president of the UK’s Royal College 
of Psychiatrists, Simon Wessely, 
told The Guardian newspaper that 
less than a third of UK patients with 
depression receive any treatment at 
all. While the figure for schizophrenia 
stands at two thirds, Wessely argued 
that there would be a public outcry 
if similar statistics applied to cancer. 
While the UK government has 
pledged “parity of esteem” for mental 
and physical healthcare, Wessely 
pointed out that the realisation of 
that promise would require funds 
to be shifted from acute provision 
to mental health, and he expressed 
doubt as to whether the necessary 
political consensus was there to 
achieve that. 
Elsewhere, there are similar 
problems. A recent study in Germany 
found that patients with mild 
depression may get medicated too 
readily, but of those with severe 
symptoms, three quarters don’t get the help they need. On the other 
hand, the study also found that 
depression is more often diagnosed in 
the wealthier and sunnier south of the 
country. Is it because those blessed 
lands are fertile ground for doctors’ 
surgeries, or do residents struggle to 
keep up with the happiness of their 
neighbours?
Causes
Depression is a complex disorder, 
and one of its complexities is that 
we don’t really understand where 
it comes from. There are obvious, 
“depressing” life events that can 
make people gloomy for a week or 
two, but such acute-phase sadness 
should be regarded as a separate 
and unrelated phenomenon — even 
though Allen Frances has warned that 
the latest edition of the Diagnostic 
and Statistical Manual, DSM-5, makes 
the mistake of blurring the boundaries 
between the two (Curr. Biol. (2013) 23, 
R295–R298).
So, if there is no acute reason to 
be gloomy, and if Western societies 
supposedly are providing wealth and 
happiness for most of their citizens, 
why has depression reached epidemic 
proportions? 
In his book The Selfish Capitalist, 
British psychologist Oliver James 
has argued that the root of the 
problem lies in the combination 
of “affluenza” — the infectious 
materialist desires beyond the 
reasonable quest for the necessary 
and useful — and the rapidly 
growing inequality which blocks 
most people from achieving the 
kind of affluence they have been 
taught to aspire to. The combined 
effects of consumerism creating 
unreasonable desires and inequality 
frustrating them is, according to 
James, a likely cause why “selfish 
capitalist” countries like the UK 
and the US now have mental illness 
rates above 20%, twice as high 
as in 1980, and also twice as high 
as those observed today in less 
selfish economies such as those of 
continental Europe. 
James’s analysis builds on Erich 
Fromm’s ideas, who in the 1950s 
postulated that the emphasis on 
Having rather than Being in Western 
society was the symptom of a sick 
society that would inevitably produce 
mental disorders. In Fromm’s 
day, there was very little scientific 
evidence to back up such theories, but the large-scale adoption of 
Thatcherite economics in the English-
speaking world since the 1980s 
constitutes an experiment whose 
unwilling participant may provide 
significant material for such analyses. 
Moreover, James lists a number of 
psychological studies conducted 
from the 1990s onwards, which have 
backed Fromm’s hypothesis that 
rampant materialism is bad for your 
mental health. 
While it is difficult to compare 
mental health statistics between 
countries and across cultural 
boundaries, James based his analysis 
on a major WHO investigation 
including 25 countries and using the 
Diagnostic and Statistical Manual of 
Mental Health (DSM) criteria as the 
uniform basis in all countries. James 
concludes that many stress factors 
of modern life, from city-dwelling 
through to the disintegration of 
traditional bonds in family, religion 
and society, contribute to the 
conditions that he prefers to call 
emotional distress rather than mental 
illness. These are shared between 
industrialised countries and may 
explain why three-quarters of the 
phenomena listed in the DSM are 
virtually unknown in pre-industrial 
societies. 
For the differences between 
nations, however, James considers 
the most likely culprit to be the 
deregulated capitalism, which has 
been most fervently embraced in 
the English-speaking countries, 
where it has driven up inequality 
and competition in the labour 
market. Compared with 1980, the 
income of the average worker has 
stalled, but people have to compete 
much harder to find work and keep 
it. At the same time, an increasing 
amount of stress arises from the 
futile attempts to fulfil material 
desires created by the advertising 
industry. 
Beyond these cultural and 
psychological factors, there are 
also neurobiological effects linked 
to depression, although it is 
difficult to establish whether they 
are causative or symptomatic. At 
the hormonal level, a depressed 
mood is manifested in a shortage 
of reward-related messengers such 
as serotonin and dopamine. Recent 
optogenetics studies (see Curr. Biol. 
(2011) 21, R831–R833) from the 
groups of Karl Deisseroth at Stanford 
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Therapy session: A patient receiving transcranial magnetic stimulation (TMS) therapy, a non-
invasive method that can improve the condition of patients with severe, drug-resistant depres-
sion. (Image: courtesy of Neuronetics, Inc.)University (Nature (2014) 493, 
537–541) and Ming-Hu Han at Mount 
Sinai School of Medicine at New 
York (Nature (2014) 493, 532–536) 
have linked dopamine neurons in the 
ventral tegmental area (VTA) of the 
rodent brain to an animal model of 
depression. 
At the brain level, a reduced 
growth of brain cells in the 
hippocampus has been observed in 
patients with depression, resulting 
in a reduced size of this part of the 
brain (Science (2012) 338, 72–75). 
Using autopsies of depression 
patients versus controls, Justin Cobb 
and colleagues at the University 
of Mississippi Medical Center in 
Jackson, USA, showed that the 
hippocampi of patients with severe 
and chronic depression had a 
significantly smaller volume than 
those of the control group. The 
neuron density was also altered, with 
an increasing density of pyramidal 
neurons in the CA1 area (J. Psychiatr. 
Res. (2013) 47, 299–306). Recently, 
Stephanie Willard and colleagues at 
Wake Forest School of Medicine in 
Winston-Salem, North Carolina, USA, 
reported characteristic changes of 
protein expression in the CA1 region 
of the hippocampi of depressed 
macaque monkeys (Neurosci. Lett. 
(2014) 563, 1–5).
Therapy options
If Fromm and James are right and 
mental illness is predominantly a 
symptom of a sick society, then 
the therapy should target the very 
system we live in. Since the financial 
crisis started in 2008, protests from 
the Occupy movement and others 
have highlighted the very same 
problems arising from the increasing 
gap between the richest 1% and the 
struggling 99%. 
However, while we are waiting for a 
landslide election result or revolution 
to change the fundamental credo of 
“selfish capitalist” countries, there 
is a large number of patients who 
urgently need medical help. There 
is no shortage of medication to 
lighten the mood of patients with 
milder cases of depression, but 
it’s the severe end of the spectrum 
that is causing concern. “The cruel 
paradox is that we are massively 
overmedicating people with mild 
depressive symptoms that will 
resolve on their own or with brief 
psychotherapy, while shamefully neglecting those who have severe 
depressions that desperately require 
more intense treatment,” says Allen 
Frances. 
As an inability to get out of bed and 
do something about one’s problems is 
often an intrinsic part of the disorder, 
patients with severe depression 
may lose treatment opportunities by 
missing appointments or failing to 
comply with their treatment schedule. 
Shortage of psychotherapists may 
mean that patients who would benefit 
from “talking therapy” such as the 
widely approved “cognitive therapy” 
(a fixed-term course that teaches 
patients to focus on positive thoughts) 
don’t get this kind of help and may 
have to resort to drugs instead. 
Whether psychotherapy, drug 
therapy or a combination of both is 
the right answer remains a highly 
contentious issue. In a recent, 
large-scale, randomised clinical 
trial involving 452 patients with 
depression, Steven Hollon from 
Vanderbilt University at Nashville 
Tennessee, with colleagues from other 
institutions, found that combining 
drug treatment with cognitive 
therapy, compared with one or 
the other, improved the outcome 
significantly for one third of patients, 
while offering little benefit for the 
other two thirds (JAMA Psychiatry 
2014, http://dx.doi.org/10.1001/
jamapsychiatry.2014.1054). Previous smaller studies and meta-
studies based on them had failed to 
resolve the question of who is most 
likely to benefit from combination 
treatment. The study by Hollon and 
colleagues could clearly show that 
the advantage of combination therapy 
over drugs-only treatment is only 
detectable for severe, non-chronic 
depression.
The combined approach is already 
part of clinical practice for severe 
depression in the UK, but not in the 
US. With the results from this clinical 
trial it will now be easier to target the 
approach to those patients most likely 
to benefit. 
In a significant number of 
patients, severe depression is 
resistant to both psychotherapeutic 
and drug treatment. For these 
cases, novel methods of stimulating 
the brain are offering a silver 
lining. One of the promising 
new approaches is transcranial 
magnetic stimulation (TMS). In 
1993, while working at the National 
Institute of Mental Health (NIMH) 
in Washington, DC, Mark George 
discovered that daily application 
of TMS to the prefrontal lobe over 
several weeks could alleviate 
depression. Since then, George and 
others have worked to develop and 
test a well-defined methodology of 
applying TMS to treat depression. 
The method was approved by the 
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While the method is already 
applied in the clinic, mostly in 
cases where repeated attempts at 
conventional therapy have failed, 
research into its benefits continues. 
In a recent randomised clinical trial 
involving suicidal inpatients at a 
military hospital, George’s group, 
now at the Medical University 
of South Carolina at Charleston, 
USA, showed that the treatment is 
feasible and safe for this particularly 
vulnerable group of patients. 
However, the suicidal thoughts 
subsided almost as quickly in the 
placebo control group (given a sham 
treatment) as in the treatment group. 
None of the patients died from 
suicide in the six months after the 
treatment (Brain Stimulation (2014) 7, 
421–431).
Studying the long-term quality 
of life outcomes of patients with 
depression after TMS treatment, 
the group of Sarah “Holly” Lisanby 
at Duke University carried out a 
randomised, sham-controlled trial 
and found that the quality of life 
improvements after TMS compared 
to sham treatment were statistically 
significant and remained so at a 
follow-up investigation six months 
after the treatment (Brain Stimulation 
(2014) 7, 219–225). 
Other treatments that may be 
used in difficult cases include 
electroconvulsive therapy (ECT, 
formerly known as electroshock 
therapy) and deep brain stimulation, 
which involves implantation of 
electrodes to deliver electrical 
impulses to specific areas of the 
brain. Compared to these measures 
of last resort, TMS has the marked 
advantage of being non-invasive and 
free of major side effects. 
Overall, the science of addressing 
the most difficult cases of 
depression is still very much in flux, 
as is our understanding of why so 
many people get depressed in the 
first place. Important discussions 
are to be had about how healthy or 
sane our Western culture is, where 
many millions aspire to the gilded 
lifestyle of celebrities, even if the 
very same celebrities are driven to 
despair. 
Michael Gross is a science writer based at 
Oxford. He can be contacted via his web 
page at www.michaelgross.co.ukEssays
Our ever-growing knowledge about the human brain and human behavior is 
opening doors to increasingly impressive technological achievements. This 
neurobiological inspiration has a significant history and involves almost equal 
parts neuroscience, computation and art. With a focus on the sense of vision, 
this essay presents a selective and highly condensed snapshot of the history of 
how neurobiology has inspired technological developments, pointing the way to 
where new inspirations may lead.
It’s all about the constraintsJohn K. Tsotsos
Discoveries about the brain, its 
function and human behavior 
are being made at an amazing 
rate. This special issue is about 
how our increasing knowledge 
in neuroscience is fostering new 
applications and technologies. 
Perhaps more is known about the 
visual system of the brain than any 
other component, and more of the 
brain’s cortical neurons are devoted 
to visual processing than any other 
task and thus this essay will focus 
on vision. The fact that we have 
successfully built cameras using 
inspiration from the structure and 
function of our eyes encourages 
us to attempt to  re-create the rest 
of the visual system artificially. The 
quest to create artificial vision has 
now seen over a half-century of 
increasingly intense activity. Each 
discovery about human vision can 
be regarded as a hint or clue that 
might be helpful in developing a 
functioning artificial vision system. 
But there are far more experimental 
discoveries than useful clues. And 
how one translates these hints into 
real systems is also very important. 
At what level of abstraction should 
it apply? What mathematical 
formulation or computational 
construct best models the hint? How 
is the result evaluated with respect 
to its computational performance? 
What degree of faithfulness to those 
neurobiological and behavioral 
observations is most useful? 
There are no easy answers to such 
questions and success lies mainly 
with the intuition and innovation of 
the developer.
Suppose one could list all the 
hints and clues that might apply 
to the creation of a successful 
vision system, whether artificial or 
biological: let the largest oval in Figure 1 represent all of these, each 
being one of the little blobs in light 
blue. What is the nature of these 
clues? Each is some characteristic 
or a truth about visual processing, 
such as, ‘one needs to understand 
what is being seen, regardless of the 
direction from which it is viewed’, or 
stated differently, ‘perception needs 
to be invariant to viewpoint’. The 
number of such characteristics is 
very large and more examples will 
appear below. It is important to note 
that the complete set of hints is not 
yet known. 
It is also important to understand 
that not all experimental observations 
about vision are useful. We 
certainly do not need to include 
any diseases of the visual system 
or any characteristics of how 
our eyes and vision systems age 
in the development of artificial 
vision, although we can often 
learn about normal, healthy vision 
by understanding such failures. 
Each of these hints, clues and 
characteristics in a direct manner 
constrain the development of 
artificial vision. To illustrate what is 
meant by constrain here, suppose 
you wish to bake a cake. Before you 
lies the whole universe of possible 
cake designs, shapes, and so on. 
Choosing a round ten-inch cake pan 
will constrain the eventual outcome; 
the choice reduces the space of 
all possibilities that you faced to the 
smaller space of all round ten-inch 
cakes. Any subsequent decisions are 
then constrained by the round pan, 
and as more decisions are taken — 
chocolate, three-layers, mocha 
frosting, and so on — the space 
of possible cakes shrinks until a 
single cake (the one you will actually 
bake) remains. In the same manner, 
any choice of neurobiological 
or behavioral hints to use in an 
artificial vision system constrains 
